NCT03916393 - PF-06651600 Taste Study. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 15, 2019

Primary Completion Date

May 10, 2019

Study Completion Date

May 10, 2019

Conditions

Healthy Participants

Interventions

DRUG

PF-06651600 20 mg

PF-06651600 in four (4) different oral formulations will be administered in different periods.

OTHER

Bitrex solution

Bitrex solution at 0.5 ppm will be included in the treatment sequence together with the four PF-06651600 formulations.

Trial Locations (1)

Pfizer Clinical Research Unit, Brussels